- Home
- SAIH vs BIAF Comparison
SAIH vs BIAF Comparison
Compare SAIH & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- BIAF
- Stock Information
- Founded
- SAIH 2019
- BIAF 2014
- Country
- SAIH Singapore
- BIAF United States
- Employees
- SAIH N/A
- BIAF N/A
- Industry
- SAIH
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SAIH
- BIAF Health Care
- Exchange
- SAIH NYSE
- BIAF Nasdaq
- Market Cap
- SAIH 12.3M
- BIAF 12.2M
- IPO Year
- SAIH N/A
- BIAF 2022
- Fundamental
- Price
- SAIH $7.20
- BIAF $0.30
- Analyst Decision
- SAIH
- BIAF Hold
- Analyst Count
- SAIH 0
- BIAF 1
- Target Price
- SAIH N/A
- BIAF N/A
- AVG Volume (30 Days)
- SAIH 20.2K
- BIAF 11.2M
- Earning Date
- SAIH 04-28-2025
- BIAF 08-13-2025
- Dividend Yield
- SAIH N/A
- BIAF N/A
- EPS Growth
- SAIH N/A
- BIAF N/A
- EPS
- SAIH N/A
- BIAF N/A
- Revenue
- SAIH $5,543,000.00
- BIAF $8,809,228.00
- Revenue This Year
- SAIH N/A
- BIAF N/A
- Revenue Next Year
- SAIH N/A
- BIAF $20.00
- P/E Ratio
- SAIH N/A
- BIAF N/A
- Revenue Growth
- SAIH N/A
- BIAF 78.40
- 52 Week Low
- SAIH $3.00
- BIAF $0.16
- 52 Week High
- SAIH $26.98
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- BIAF 50.96
- Support Level
- SAIH N/A
- BIAF $0.22
- Resistance Level
- SAIH N/A
- BIAF $0.46
- Average True Range (ATR)
- SAIH 0.00
- BIAF 0.04
- MACD
- SAIH 0.00
- BIAF 0.01
- Stochastic Oscillator
- SAIH 0.00
- BIAF 30.51
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.